1-20 of 24
Valeria Magarotto
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report

Stefano Molica, Potito Rosario Scalzulli, Lydia Scarfo, Attilio Guarini, Roberta Murru, Paolo Sportoletti, Ferdinando Frigeri, Francesco Albano, Nicola Di Renzo, Alessandro Sanna, Idanna Innocenti, Massimo Massaia, Marta Coscia, Elsa Pennese, Caterina Patti, Gianluigi Reda, Agostino Tafuri, Anna Grugnetti, Valeria Magarotto, Francesca Romana Mauro
Journal: Blood
Blood (2021) 138 (Supplement 1): 4684.
https://doi.org/10.1182/blood-2021-148378
Published: 2021
Journal Articles

A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients

Sara Bringhen, MD, Valeria Magarotto, MD, Anna Marina Liberati, MD, Angelo Belotti, MD, Alessandra Larocca, MD, Milena Gilestro, BSc, Francesca Bonello, MD, Gianluca Gaidano, MD PhD, Paola Bertazzoni, MD, Raffaella Stocchi, MD, Rossella Ribolla, MD, Chiara Di Sano, MD, Francesca Patriarca, Roberto Passera, PharmD, PhD, Lorenzo De Paoli, MD, Stefania Oliva, MD, Anna Maria Cafro, MD, Pieter Sonneveld, MD PhD, Antonio Palumbo, MD, Mario Boccadoro, MD
Journal: Blood
Blood (2016) 128 (22): 1145.
https://doi.org/10.1182/blood.V128.22.1145.1145
Published: 2016
Journal Articles

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Clinical Trials & Observations
Valeria Magarotto, Sara Bringhen, Massimo Offidani, Giulia Benevolo, Francesca Patriarca, Roberto Mina, Antonietta Pia Falcone, Lorenzo De Paoli, Giuseppe Pietrantuono, Silvia Gentili, Caterina Musolino, Nicola Giuliani, Annalisa Bernardini, Concetta Conticello, Stefano Pulini, Giovannino Ciccone, Vladimír Maisnar, Marina Ruggeri, Renato Zambello, Tommasina Guglielmelli, Antonio Ledda, Anna Marina Liberati, Vittorio Montefusco, Roman Hajek, Mario Boccadoro, Antonio Palumbo
Journal: Blood
Blood (2016) 127 (9): 1102–1108.
https://doi.org/10.1182/blood-2015-08-662627
Published: 2016
Includes: Supplemental data
Journal Articles

Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial

Francesca Gay, Valeria Magarotto, MD, Maria Teresa Petrucci, Francesco Di Raimondo, Luděk Pour, Tommaso Caravita, Vlastimil Scudla, Anna Maria Cafro, Anna Marina Liberati, Stefano Spada, Maisnar Vladimir, Norbert Pescosta, Roberto Ria, Massimo Offidani, Sara Bringhen, Annalisa Bernardini, Francesca Patriarca, Paolo Corradini, Roberto Foà, Nicola Cascavilla, Lucio Catalano, Andrew Spencer, Roman Hajek, Mario Boccadoro, MD, Antonio Palumbo
Journal: Blood
Blood (2015) 126 (23): 392.
https://doi.org/10.1182/blood.V126.23.392.392
Published: 2015
Journal Articles

Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients

Roberto Mina, Alessandra Larocca, Massimo Offidani, Sara Bringhen, Tommaso Caravita, Valeria Magarotto, MD, Lucia Pantani, MD, Francesco Di Raimondo, Alberto Bosi, Iolanda D. Vincelli, Paola Tacchetti, MD, Gianluca Gaidano, Sonia Grandi, Caterina Musolino, Chiara Cerrato, Ludek Pour, Monica Astolfi, Giuseppe Rossi, MD, Fausto Rossini, Maria T. Petrucci, Roberto Ria, Annalisa Pezzi, PhD, Roman Hajek, Michele Cavo, Andrew Spencer, Mario Boccadoro, MD, Antonio Palumbo
Journal: Blood
Blood (2015) 126 (23): 927.
https://doi.org/10.1182/blood.V126.23.927.927
Published: 2015
Journal Articles

Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival

Peter M. Voorhees, MD, Valeria Magarotto, MD, Pieter Sonneveld, MD PhD, Torben Plesner, MD, Ulf-Henrik Mellqvist, MD PhD, Claudia E. Paba-Prada, MD, Catriona Byrne, RN, Johan Harmenberg, MDPhD, Eva Nordstrom, MSc,MBA, Antonio Palumbo, MD, Paul Richardson, MD
Journal: Blood
Blood (2015) 126 (23): 3029.
https://doi.org/10.1182/blood.V126.23.3029.3029
Published: 2015
Journal Articles

The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease

Elena Zamagni, MD, Cristina Nanni, MD, Francesca Gay, MD, Annalisa Pezzi, Statistician, Marilena Bellò, MD, Ilaria Rambaldi, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Lucia Pantani, MD, Valeria Magarotto, MD, Beatrice Anna Zannetti, MD, Massimo Menga, MD, Giulia Marzocchi, PhD, Carolina Terragna, PhD, Katia Mancuso, MD, Antonio Palumbo, MD, Stefano Fanti, MD, Michele Cavo, MD
Journal: Blood
Blood (2014) 124 (21): 3371.
https://doi.org/10.1182/blood.V124.21.3371.3371
Published: 2014
Journal Articles

Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study

Valeria Magarotto, MD, Sara Bringhen, MD, Pellegrino Musto, MD, Massimo Offidani, MD, Anna Marina Liberati, MD, Ludek Pour, MD, Giulia Benevolo, MD, Mariella Genuardi, MD, Caterina Musolino, Antonio Ledda, MD, Daniela Oddolo, PhD, Lorenzo De Paoli, MD, Francesca Patriarca, MD, Antonietta Pia Falcone, MD, Isola Caratozzolo, Renato Zambello, MD, Maide Cavalli, MD, Silvia Gentili, MD, Roman Hajek, Mario Boccadoro, MD, Antonio Palumbo, MD
Journal: Blood
Blood (2014) 124 (21): 2110.
https://doi.org/10.1182/blood.V124.21.2110.2110
Published: 2014
Journal Articles

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Clinical Trials & Observations
Sara Bringhen, Maria Teresa Petrucci, Alessandra Larocca, Concetta Conticello, Davide Rossi, Valeria Magarotto, Pellegrino Musto, Luana Boccadifuoco, Massimo Offidani, Paola Omedé, Fabiana Gentilini, Giovannino Ciccone, Giulia Benevolo, Mariella Genuardi, Vittorio Montefusco, Stefania Oliva, Tommaso Caravita, Paola Tacchetti, Mario Boccadoro, Pieter Sonneveld, Antonio Palumbo
Journal: Blood
Blood (2014) 124 (1): 63–69.
https://doi.org/10.1182/blood-2014-03-563759
Published: 2014
Includes: Supplemental data
Journal Articles

Circulating Mir- 16 and Mir- 25 As New Prognosticators For Multiple Myeloma

Flavia Pichiorri, PhD, Alberto Rocci, Craig C Hofmeister, MD, Susan Geyer, PhD, Tiffany Talabere, PhD, Massimiliano Gambella, Luciano Cascione, PhD, Andrew Stiff, BS, Don M. Benson, Jr., MD, PhD, Yvonne A Efebera, MD, Vijaya Dirisala, PhD, Emily M Smith, BS, Paola Omedè, B.S., Pellegrino Musto, MD, Davide Rossi, Silvia Gentili, MD, Giuseppina Uccello, MD, Roberto Ria, MD, Giulia Benevolo, MD, Sara Bringhen, MD, Vincenzo Callea, Brendan M Weiss, MD, Alfredo Ferro, Valeria Magarotto, PhD, Hansjuerg Alder, PhD, John C. Byrd, MD, Mario Boccadoro, MD, Guido Marcucci, MD, Antonio Palumbo
Journal: Blood
Blood (2013) 122 (21): 1853.
https://doi.org/10.1182/blood.V122.21.1853.1853
Published: 2013
Journal Articles

A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients

Antonio Palumbo, MD, Valeria Magarotto, Sara Bringhen, MD, Massimo Offidani, MD, Giuseppe Pietrantuono, MD, Anna Marina Liberati, MD, Giulia Benevolo, MD, Antonio Ledda, MD, Milena Gilestro, Monica Galli, MD, Francesca Patriarca, MD, Mariella Genuardi, MD, Nicola Giuliani, MD, Renato Zambello, MD, Adam Zdenek, Alessia La Fauci, MD, Paolo Corradini, Antonietta Pia Falcone, MD, Caterina Musolino, MD, Davide Rossi, MD, Ph.D., Patrizia Caraffa, MD, Pellegrino Musto, MD, Federica Cavallo, MD, Roman Hajek, MD, PhD, Mario Boccadoro, MD
Journal: Blood
Blood (2013) 122 (21): 536.
https://doi.org/10.1182/blood.V122.21.536.536
Published: 2013
Journal Articles

Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosfamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age

Alessandra Larocca, MD, Federica Cavallo, MD, Valeria Magarotto, MD, Massimo Offidani, MD, Vincenzo Federico, MD, Vanessa Innao, MD, Antonietta Pia Falcone, MD, Alessandra Romano, MD, Tommaso Caravita, MD, Davide Rossi, MD, Giovanna Mansueto, MD, Roberto Mina, MD, Chiara Nozzoli, MD, Giulia Benevolo, MD, Tommasina Guglielmelli, MD, Anna Marina Liberati, MD, Daniele Derudas, MD, Stefania Oliva, Fortunato Morabito, MD, Angelo Michele Carella, MD, Silvia Gentili, MD, Elona Saraci, Maria Teresa Petrucci, MD, Pieter Sonneveld, MD, Ph.D, Mario Boccadoro, MD, Antonio Palumbo, MD
Journal: Blood
Blood (2013) 122 (21): 539.
https://doi.org/10.1182/blood.V122.21.539.539
Published: 2013
Journal Articles

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

Clinical Trials & Observations
Alessandra Larocca, Vittorio Montefusco, Sara Bringhen, Davide Rossi, Claudia Crippa, Roberto Mina, Monica Galli, Magda Marcatti, Giacinto La Verde, Nicola Giuliani, Valeria Magarotto, Tommasina Guglielmelli, Delia Rota-Scalabrini, Paola Omedé, Alberto Santagostino, Ileana Baldi, Angelo Michele Carella, Mario Boccadoro, Paolo Corradini, Antonio Palumbo
Journal: Blood
Blood (2013) 122 (16): 2799–2806.
https://doi.org/10.1182/blood-2013-03-488676
Published: 2013
Includes: Supplemental data
Journal Articles

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results

Clinical Trials & Observations
Francesca Gay, Valeria Magarotto, Claudia Crippa, Norbert Pescosta, Tommasina Guglielmelli, Federica Cavallo, Sara Pezzatti, Samantha Ferrari, Anna Marina Liberati, Stefania Oliva, Francesca Patriarca, Massimo Offidani, Paola Omedé, Vittorio Montefusco, Maria Teresa Petrucci, Nicola Giuliani, Roberto Passera, Giuseppe Pietrantuono, Mario Boccadoro, Paolo Corradini, Antonio Palumbo
Journal: Blood
Blood (2013) 122 (8): 1376–1383.
https://doi.org/10.1182/blood-2013-02-483073
Published: 2013
Includes: Supplemental data
Journal Articles

Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients

Antonio Palumbo, MD, Sara Bringhen, Davide Rossi, MD, Maide Cavalli, MD, Roberto Ria, MD, Silvia Gentilini, MD, Francesca Patriarca, Chiara Nozzoli, MD, Anna Levi, MD, Tommasina Guglielmelli, MD, Giulia Benevolo, MD, Donatella Vincelli, MD, Luca Baldini, Fortunato Morabito, MD, Mariella Grasso, MD, Roberto Marasca, MD, Manuela Rizzo, MD, Chiara Pautasso, Pharm D, Antonietta Pia Falcone, MD, Daniela Gottardi, MD, Vittorio Montefusco, MD, Caterina Musolino, MD, Clotilde Cangialosi, MD, Giovanna Mansueto, MD, Anna Marina Liberati, MD, Valeria Magarotto, MD, Paola Omedè, PhD, Pellegrino Musto, MD, Maria Teresa Petrucci, MD, Mario Boccadoro, MD
Journal: Blood
Blood (2012) 120 (21): 200.
https://doi.org/10.1182/blood.V120.21.200.200
Published: 2012
Journal Articles

Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors

Antonio Palumbo, Sara Bringhen, Maide Cavalli, Roberto Ria, Massimo Offidani, Francesca Patriarca, Chiara Nozzoli, Tommasina Guglielmelli, Giulia Benevolo, Vincenzo Callea, Renato Zambello, Giuseppe Pietrantuono, Luca De Rosa, Anna Marina Liberati, Claudia Crippa, Giulia Perrone, Fabrizio Ciambelli, Angelo Michele Carella, Salvatore Palmieri, Milena Gilestro, Valeria Magarotto, Maria Teresa Petrucci, Pellegrino Musto, Gianluca Gaidano, Mario Boccadoro
Journal: Blood
Blood (2010) 116 (21): 620.
https://doi.org/10.1182/blood.V116.21.620.620
Published: 2010
Journal Articles

Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients.

Antonio Palumbo, Sara Bringhen, Davide Rossi, Roberto Ria, Massimo Offidani, Francesca Patriarca, Chiara Nozzoli, Anna Levi, Tommasina Guglielmelli, Giulia Benevolo, Vincenzo Callea, Barbara Olivero, Fortunato Morabito, Mariella Grasso, Roberto Marasca, Manuela Rizzo, Antonietta Pia Falcone, Daniela Gottardi, Vittorio Montefusco, Caterina Musolino, Renato Zambello, Clotilde Cangialosi, Giuseppe Pietrantuono, Valeria Magarotto, Maria Teresa Petrucci, Pellegrino Musto, Giovannino Ciccone, Francesco Di Raimondo, Gianluca Gaidano, Mario Boccadoro
Journal: Blood
Blood (2009) 114 (22): 128.
https://doi.org/10.1182/blood.V114.22.128.128
Published: 2009
Journal Articles

Inhibition of Interleukin-6 Signaling with CNTO 328 Sensitizes Plasma Cell Dyscrasias to the Effects of Melphalan in Association with Suppression of Signaling through Protein Kinase B/Akt.

Sally A. Hunsucker, Ph.D., Valeria Magarotto, M.D., Jairo A. Matthews, B.A., Michael Wang, M.D., Veerabhadran Baladandayuthapani, Ph.D., Peter M. Voorhees, M.D., Hong Xie, M.D., Mark Cornfeld, M.D., M.P.H., Jeffrey A. Nemeth, M.D., Ph.D., Robert Z. Orlowski, M.D., Ph.D.
Journal: Blood
Blood (2009) 114 (22): 1836.
https://doi.org/10.1182/blood.V114.22.1836.1836
Published: 2009
Journal Articles

Impact of Baseline Free Light Chain Ratio (rFLC) On Clinical Outcomes and Change in rFLC During Treatment in Patients with Relapsed/Refractory Multiple Myeloma Treated with Pegylated Liposomal Doxorubicin Plus Bortezomib or Bortezomib Alone.

Valeria Magarotto, MD, Anil Londhe, PhD, Keith C. Lantz, MS, Colin Lowery, DPhil, Pieter Sonneveld, MD, PhD, Joan Bladé, MD, Jean-Luc Harousseau, MD, Robert Z. Orlowski, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 4778.
https://doi.org/10.1182/blood.V114.22.4778.4778
Published: 2009
Journal Articles

Bortezomib Resistance Is Mediated by Increased Signaling through the Insulin-Like Growth Factor-1/Akt Axis.

Deborah J. Kuhn, Ph.D., Chad C. Bjorklund, Ph.D., Valeria Magarotto, M.D., Jairo A. Matthews, B.A., Michael Wang, M.D., Veerabhadran Baladandayuthapani, Ph.D., Robert Z. Orlowski, M.D., Ph.D.
Journal: Blood
Blood (2009) 114 (22): 2739.
https://doi.org/10.1182/blood.V114.22.2739.2739
Published: 2009